Physician profile
Simon Badin
NPI 1467699405
$5,149.25
in general payments reported to CMS, 2019-2025
49 companies · $52.45 in 2025
The $52.45 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $794 · 2020: $1,006 · 2021: $1,280 · 2022: $1,265 · 2023: $600 · 2024: $153 · 2025: $52.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $606 · Long Term Medical Supply Or Device Loan: $183 · Education: $16.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $605.56 |
| Long Term Medical Supply Or Device Loan | $183.03 |
| Education | $16.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $782.42 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $531.81 | 2019-2023 | Opdivo |
| Astrazeneca Pharmaceuticals Lp | $492.79 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $472.92 | 2019-2022 | |
| Novo Nordisk INC | $265.54 | 2019-2023 | |
| Janssen Biotech, INC. | $216.62 | 2019-2024 | Darzalex, Imbruvica |
| Amgen INC. | $213.25 | 2019-2022 | |
| Glaxosmithkline, LLC. | $199.98 | 2020-2024 | Trelegy Ellipta |
| Pfizer INC. | $184.44 | 2019-2024 | |
| Incyte Corporation | $159.26 | 2019-2022 | |
| Celgene Corporation | $146.60 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $143.93 | 2019-2025 | |
| Ge Healthcare | $81.67 | 2022 | |
| Genentech USA, INC. | $78.57 | 2020-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $77.69 | 2021-2022 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simon Badin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.